Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

SUNPHARMA NSE

Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.[1] It is the largest pharmaceutical company in India.[2]

AI Verdict: BUY Confidence: 7%

Sun Pharma commands a market cap of ₹4,48,412 Cr with consistent profit compounding at 17% CAGR over 5 years and near-zero debt. While the PE of 38.9x is elevated and sales growth remains modest at 12% over 5 years, the overwhelming analyst consensus (87.9% buy) and steady ROE of 16% support a buy with a medium risk profile.

Key Fundamentals

LargecapPharmaceuticalsHealthcare
Market Cap
4.5L Cr
Volatility
Moderate
P/E Ratio
38.93
EBITDA
₹16,182 Cr
Return on Equity
14.38%
Debt to Equity
0.04
Book Value
₹348.31
EPS
₹43.95
52W High
₹1,916.6
52W Low
₹1,548

Technical Indicators

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 34.1%

Weaknesses

2
  • The company has delivered a poor sales growth of 11.8% over past five years.
  • Working capital days have increased from 102 days to 185 days

Growth Rate

Revenue Growth
6.38% ↗
Net Income Growth
5.32% ↗
Cash Flow Change
15.96% ↗
ROE
5.43% ↗
ROCE
14.46% ↗
EBITDA Margin (Avg.)
-14.64% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 1d ago
BUY
Risk medium

Sun Pharma commands a market cap of ₹4,48,412 Cr with consistent profit compounding at 17% CAGR over 5 years and near-zero debt. While the PE of 38.9x is elevated and sales growth remains modest at 12% over 5 years, the overwhelming analyst consensus (87.9% buy) and steady ROE of 16% support a buy with a medium risk profile.

Bull Case 8
  • Near debt-free balance sheet provides financial flexibility and resilience during downturns
  • 5-year compounded profit growth of 17% significantly outpaces sales growth, indicating expanding margins
  • Overwhelming analyst consensus with 87.88% buy ratings (29 out of 33 analysts recommend buy)
  • Consistent ROE of 16% maintained over 3 and 5 year periods, demonstrating stable return generation
  • Healthy dividend payout ratio of 34.1% with current yield of 0.86%, rewarding shareholders consistently
  • Stock CAGR of 24% over 3 years and 23% over 5 years reflects strong price momentum and investor confidence
  • TTM sales growth of 11% shows continued revenue traction in the current period
  • 10-year compounded profit growth of 10% demonstrates long-term earnings sustainability across cycles
Bear Case 8
  • PE ratio of 38.9x is significantly above the pharma sector average of ~25-30x, leaving limited margin of safety
  • Working capital days have deteriorated sharply from 102 days to 185 days, signaling potential cash conversion issues
  • 5-year compounded sales growth of only 12% is modest for a company trading at nearly 40x earnings
  • Price-to-book ratio of 5.36x indicates the stock is priced at a steep premium to book value
  • TTM profit growth has decelerated to 9% compared to 13% over 3 years and 17% over 5 years
  • 10-year stock CAGR of only 9% suggests prolonged periods of underperformance in the past
  • Dividend yield of 0.86% offers limited income cushion relative to the elevated valuation multiple
  • Only 10-year sales CAGR of 7% highlights structural challenges in sustaining top-line acceleration

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 1d ago
Headwinds 2
  • West Asia war, logistics cost risk May 25

    Sun Pharma declined to provide margin guidance citing rising logistics/shipping costs and West Asia war impact. FY27 outlook projects only high single-digit top-line growth with R&D at 6-7% of sales.

  • Independent director arrested Jun 14

    Independent Director Gautam Doshi was arrested. Company stated the matter is unrelated to operations, but it adds governance overhang.

Positives 3
  • UNLOXCYT shows 50% response rate May 26

    Updated UNLOXCYT data presented at ASCO 2026 showed 50% objective response rate with durable responses in laCSCC patients and manageable safety profile.

  • Acquires Innovcare for ₹271.2 crore Jun 20

    Sun Pharma agreed to acquire 100% of Innovcare Lifesciences for ₹271.2 crore to strengthen its product portfolio.

  • ₹5 dividend, record date Jul 7 Jun 11

    Final dividend of ₹5 per share for FY25-26 with record date July 7, 2026. 34th AGM scheduled for July 31, 2026.

Neutral 2
  • Block trades signal institutional interest Jun 15

    Two block trades on NSE — ₹18.96 crore (1,05,229 shares at ₹1802.10) on Jun 15 and ₹19.03 crore (1,06,240 shares at ₹1790.90) on Jun 3 — indicate steady institutional activity.

  • Analyst meet at 360 ONE conference May 25

    Sun Pharma held an analyst and institutional investor meeting on May 27, 2026 in Mumbai as part of the 360 ONE Capital 16th Annual Investor Conference.

TL;DR: Sun Pharma is delivering on its specialty pipeline with strong UNLOXCYT clinical data and pursuing inorganic growth via the Innovcare acquisition. Key risks include margin pressure from geopolitical disruptions in West Asia and rising logistics costs, with management notably withholding margin guidance. Institutional activity remains steady and the dividend signals confidence in cash flows. The innovation pipeline is a clear positive, but near-term margin visibility remains clouded until geopolitical headwinds ease.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
10,931
11,941
12,192
12,381
11,983
12,653
13,291
13,675
12,959
13,851
14,478
15,521
14,612
Expenses
8,129
8,609
9,013
8,904
8,948
9,045
9,352
9,666
9,243
9,550
9,951
10,572
10,658
Operating Profit
2,802
3,332
3,179
3,477
3,035
3,608
3,939
4,009
3,716
4,302
4,527
4,948
3,954
OPM %
26%
28%
26%
28%
25%
29%
30%
29%
29%
31%
31%
32%
27%
Other Income
202
-118
294
180
504
533
354
149
251
-354
470
89
458
Interest
93
81
49
35
74
62
69
52
49
75
100
78
86
Depreciation
672
651
633
622
650
655
626
631
664
701
730
732
775
PBT
2,240
2,481
2,791
3,000
2,816
3,424
3,598
3,476
3,254
3,173
4,168
4,227
3,551
Tax %
10%
19%
14%
14%
5%
16%
16%
16%
34%
27%
25%
20%
23%
Net Profit
1,983
2,006
2,385
2,561
2,659
2,861
3,037
2,913
2,154
2,293
3,125
3,381
2,710
EPS in Rs
8.27
8.43
9.9
10.52
11.06
11.82
12.67
12.1
8.96
9.5
13
14.04
11.31
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
27,392
28,487
31,578
26,489
29,066
32,838
33,498
38,654
43,886
48,497
52,578
58,462
Expenses
19,498
20,313
21,476
20,858
22,689
25,855
25,028
28,397
32,235
35,479
37,464
40,731
Operating Profit
7,894
8,174
10,102
5,631
6,377
6,983
8,470
10,258
11,650
13,018
15,114
17,731
OPM %
29%
29%
32%
21%
22%
21%
25%
27%
27%
27%
29%
30%
Other Income
283
-42
610
-135
-258
382
-3,449
-3,505
459
865
1,444
664
Interest
579
523
400
518
555
303
141
127
172
238
231
339
Depreciation
1,195
1,038
1,265
1,500
1,753
2,053
2,080
2,144
2,529
2,557
2,575
2,938
PBT
6,403
6,571
9,048
3,479
3,810
5,010
2,799
4,481
9,408
11,088
13,752
15,119
Tax %
14%
14%
13%
26%
16%
16%
18%
24%
9%
13%
20%
24%
Net Profit
5,476
5,658
7,846
2,542
3,208
4,172
2,272
3,389
8,513
9,610
10,965
11,509
EPS in Rs
21.92
18.89
29.03
8.73
11.11
15.69
12.1
13.64
35.32
39.91
45.55
47.84
Div. Payout %
14%
5%
12%
23%
25%
25%
62%
73%
33%
34%
35%
33%
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
207
241
240
240
240
240
240
240
240
240
240
240
Reserves
25,431
32,742
36,400
38,074
41,169
45,025
46,223
47,771
55,755
63,427
71,978
83,330
Borrowings
8,996
8,497
9,832
10,385
10,514
8,315
3,869
1,290
6,886
3,274
2,362
4,627
Other Liabilities
14,089
13,948
14,624
15,598
12,666
14,615
17,291
20,474
17,831
18,387
17,328
20,588
Total Liabilities
48,723
55,428
61,095
64,297
64,590
68,194
67,622
69,776
80,712
85,328
91,908
1,08,785
Fixed Assets
12,682
15,872
17,675
18,853
21,837
22,847
21,553
22,665
24,065
23,248
22,586
34,493
CWIP
2,039
2,175
2,801
2,465
1,411
1,220
1,567
1,287
4,973
5,354
6,644
1,381
Investments
2,716
1,830
1,192
7,143
7,903
10,143
9,612
12,849
14,824
15,026
18,354
24,723
Other Assets
31,286
35,550
39,427
35,837
33,439
33,984
34,890
32,975
36,849
41,700
44,324
48,189
Total Assets
48,723
55,428
61,095
64,297
64,590
68,194
67,622
69,776
80,712
85,328
91,908
1,08,785
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
5,616
6,686
7,082
3,907
2,196
6,555
6,170
8,985
4,959
12,135
14,072
12,419
Investing
-1,502
-3,949
-4,186
-3,104
-310
-2,225
407
-5,556
-7,220
-763
-5,183
-11,344
Financing
-1,187
-1,889
-2,285
-1,539
-2,731
-5,715
-5,980
-5,193
2,376
-6,710
-7,906
-2,513
Net Cash Flow
2,927
848
611
-736
-844
-1,386
596
-1,765
115
4,662
983
-1,437
Free Cash Flow
3,316
3,353
3,492
2,013
-966
5,105
5,097
7,550
2,895
9,964
12,005
8,906
CFO/OP
93
106
90
83
48
113
85
78
56
105
96
83
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
68
87
83
108
112
105
99
99
95
85
91
97
Inventory Days
307
370
307
338
366
311
378
315
360
338
348
363
Days Payable
178
207
197
234
192
142
167
158
194
194
210
232
Cash Conversion Cycle
197
251
193
212
285
274
310
255
261
229
228
228
Working Capital Days
-7
37
-4
-31
31
51
51
47
40
55
65
185
ROCE %
23%
18%
20%
10%
10%
10%
13%
17%
16%
17%
20%
21%

Shareholding Pattern

As of Mar 2026
Promoters 54.48%
DIIs 21.11%
FIIs 15.93%
Public 5.30%
Others 3.18%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
54.48%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
16.79%
0.00%
17.72%
17.23%
18.02%
18.05%
17.96%
17.26%
16.55%
16.12%
15.93%
DIIs
21.59%
21.93%
21.67%
20.94%
19.94%
19.57%
18.60%
19.14%
19.24%
19.75%
19.67%
17.97%
18.83%
19.28%
18.61%
18.55%
18.70%
19.50%
20.24%
20.82%
21.11%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
7.34%
7.21%
6.79%
6.68%
6.49%
6.31%
5.91%
5.76%
5.70%
5.65%
5.56%
5.41%
5.44%
5.57%
5.43%
5.47%
5.42%
5.35%
5.53%
5.40%
5.30%
Others
16.60%
16.38%
17.05%
17.90%
19.09%
19.64%
21.01%
20.63%
20.58%
20.12%
3.51%
22.13%
3.53%
3.44%
3.46%
3.46%
3.45%
3.42%
3.20%
3.18%
3.18%
No. of Shareholders
0
7,09,045
7,57,366
6,75,908
6,80,800
6,62,384
6,47,167
6,43,512
6,25,252
6,24,561
6,16,588
6,12,626
6,31,392
6,73,217
6,57,317
6,89,623
7,04,983
7,23,770
7,43,877
7,10,900
6,90,957

Documents

Frequently Asked Questions about Sun Pharmaceutical Industries Ltd

What does Sun Pharmaceutical Industries Ltd do?
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading...
Where is Sun Pharmaceutical Industries Ltd (SUNPHARMA) listed?
Sun Pharmaceutical Industries Ltd is listed on the Indian stock exchanges. It is listed on NSE: SUNPHARMA and BSE: 524715. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Sun Pharmaceutical Industries Ltd belong to?
Sun Pharmaceutical Industries Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Sun Pharmaceutical Industries Ltd?
Sun Pharmaceutical Industries Ltd has a market capitalisation of approximately ₹448747.62 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Sun Pharmaceutical Industries Ltd?
The Price-to-Earnings (PE) ratio of Sun Pharmaceutical Industries Ltd is 38.93. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Sun Pharmaceutical Industries Ltd?
Over the past 52 weeks, Sun Pharmaceutical Industries Ltd has traded between a low of ₹1,548 and a high of ₹1,916.6. This range helps investors understand the stock's price volatility and recent trading levels.
Does Sun Pharmaceutical Industries Ltd pay dividends?
Yes, Sun Pharmaceutical Industries Ltd has a dividend yield of 0.85%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Sun Pharmaceutical Industries Ltd?
Sun Pharmaceutical Industries Ltd has a Return on Equity (ROE) of 14.38%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Sun Pharmaceutical Industries Ltd on Tapetide?
On Tapetide, you can view Sun Pharmaceutical Industries Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.[1] It is the largest pharmaceutical company in India.[2]

Website sunpharma.com
CEO Mr. Dilip Shantilal Shanghvi
Employees 43,000
Listed 1995-02-08
Face Value ₹ 1
Issued Size 2,39,93,34,970

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List